Savara announces first patient dosed in pivotal phase 3 autoimmune pulmonary alveolar proteinosis (apap) trial

Austin, texas--(business wire)--savara inc. (nasdaq: svra), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal impala-2 clinical trial. impala-2 is a phase 3 trial designed to evaluate the efficacy and safety of molgramostim compared to placebo. molgramostim is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (gm-csf). the trial is expected to be conduct
SVRA Ratings Summary
SVRA Quant Ranking